Clinical Trials Sponsored by Hrain Biotechnology

Total 1713 results

Hrain Biotechnology Co., Ltd.
Ruijin Hospital

Not yet recruiting

To Evaluate the Safety and Tolerability of Human CD19-CD22 Targeted T Cells Injection for Subjects With R/R B-ALL.

Acute Lymphoblastic Leukemia

China
Hrain Biotechnology Co., Ltd.
Shanghai Changzheng Hospital

Recruiting

To Evaluate the Safety and Efficacy of Human BCMA Targeted CAR-NK Cells Injection for Subjects With R/R MM or PCL

Multiple Myeloma | Plasma Cell Leukemia

China
Hrain Biotechnology Co., Ltd.
Shanghai Changzheng Hospital

Recruiting

To Evaluate the Safety and Efficacy of Human Derived Anti-BCMA CAR-T Injection for Subjects With R/R MM

Multiple Myeloma

China
Hrain Biotechnology Co., Ltd.
Shanghai Changzheng Hospital

Recruiting

BCMA Chimeric Antigen Receptor Expressing T Cells Therapy for Relapsed/Refractory Multiple Myeloma

Multiple Myeloma

China
Hrain Biotechnology Co., Ltd.
Shanghai Zhongshan Hospital

Recruiting

Human CD19 Targeted T Cells Injection(CD19 CAR-T) Therapy for Relapsed and Refractory B-cell Non-Hodgkin's Lymphoma

B-cell Non-Hodgkin's Lymphoma

China
Hrain Biotechnology Co., Ltd.
Shanghai Changzheng Hospital

Active, not recruiting

Anti-CD19/BCMA Bispecific CAR-T Cell Therapy for R/R POMES

POMES Syndrome | Relapsed and Refractory POMES Syndrome

China
Hrain Biotechnology Co., Ltd.
Shanghai Zhongshan Hospital

Recruiting

Human CD19 Targeted T Cells Injection(CD19 CAR-T) Therapy for Relapsed and Refractory CD19-positive Lymphoma.

Follicular Lymphoma | Diffuse Large B-cell Lymphoma | CD19-positive

China
Shanghai 6th People's Hospital
Hrain Biotechnology Co., Ltd.

Recruiting

The Fourth Generation CART-cell Therapy for Refractory-Relapsed Ovarian Cancer

Ovarian Cancer

China
Beijing Sanbo Brain Hospital
Marino Biotechnology Co., Ltd.

Unknown

Pilot Study of Autologous Chimeric Switch Receptor Modified T Cells in Recurrent Glioblastoma Multiforme

Glioblastoma Multiforme

China
Hrain Biotechnology Co., Ltd.
Second Affiliated Hospital of Nanchang University

Recruiting

To Evaluate the Safety and Efficacy of Human CD19 Targeted DASH CAR-T Cells Injection for Subjects With R/R B-ALL

B-cell Acute Lymphoblastic Leukemia

China
Hrain Biotechnology Co., Ltd.
Second Affiliated Hospital of Nanchang University

Recruiting

Human CD19-CD22 Targeted T Cells Injection for Refractory/Relapsed Central Nervous System Leukemia/Lymphoma Patients

Central Nervous System Lymphoma

China
Peng Liu
Shanghai East Hospital; Hrain Biotechnology

Unknown

Anti-CD19/BCMA Bispecific CAR-T Cell Therapy for R/R MM

Multiple Myeloma in Relapse | Multiple Myeloma Progression

China
Beijing Sanbo Brain Hospital
Marino Biotechnology Co., Ltd.

Unknown

Pilot Study of Autologous Anti-EGFRvIII CAR T Cells in Recurrent Glioblastoma Multiforme

Glioblastoma Multiforme

China
Cellxpert Biotechnology Corp.
Medigen Biotechnology Corporation

Completed

Trial of PI-88 With Docetaxel in Advanced Non-Small-Cell Lung Cancer (NSCLC)

Carcinoma, Non-Small-Cell Lung

Australia
Hrain Biotechnology Co., Ltd.
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine

Recruiting

Human CD19 Targeted T Cells Injection Therapy for Relapsed and Refractory CD19-positive Leukemia

Acute Lymphoblastic Leukemia | CD19-positive

China
Hrain Biotechnology Co., Ltd.
First Affiliated Hospital of Wenzhou Medical University; Shanghai Changzheng...

Recruiting

Human BCMA Targeted T Cells Injection（BCMA CAR-T）for Subjects With R/R MM

Multiple Myeloma

China
Zhejiang University
Second Affiliated Hospital, School of Medicine, Zhejiang University; Hrain...

Unknown

MESO-CAR T Cells Therapy for Relapsed and Refractory Ovarian Cancer

Ovarian Cancer

China
Xinqiao Hospital of Chongqing
Xuzhou Medical University; Shanghai Changzheng Hospital; Hrain Biotechnology...

Unknown

Memory-enriched CAR-T Cells Immunotherapy for B Cell Lymphoma (MeCAR)

Recurrent Adult Diffuse Large Cell Lymphoma | Recurrent Mantle Cell Lymphoma | Stage III Adult Diffuse Large Cell Lymphoma | Stage III Mantle Cell Lymphoma | Stage IV Adult Diffuse Large Cell Lymphoma | Stage IV Mantle Cell Lymphoma | Recurrent Follicular Lymphoma | Stage III Follicular Lymphoma | Stage...

China
Grit Biotechnology

Recruiting

GT201 Injection in Combination With Teraplizumab Injection for Treatment of Patients With Non-small Cell Lung Cancer

Non-small Cell Lung Cancer | Adult

China
AVB Biotechnology

Recruiting

Investigation of Efficacy and Safety of Electrical Signal Therapy Provided by Dr Biolyse® Device in COVID-19 Disease (DoBiC-19)

Virus Diseases | COVID-19 | COVID-19 Pneumonia

Turkey
Grit Biotechnology

Recruiting

TIL Injection for the Treatment of Metastatic or Recurrent Solid Tumors

Solid Tumors, Adult

China
Avecho Biotechnology

Not yet recruiting

Evaluating Efficacy and Safety of CBD TPM Capsules for Use in Insomnia

Insomnia
EVIVE Biotechnology

Withdrawn

Study of F-652 in Subjects With Corona Virus Disease 2019 (COVID-19) Pneumonia

COVID-19 Pneumonia
EVIVE Biotechnology

Completed

Neulasta-controlled Trial of F-627 in Women With Breast Cancer Receiving Myelotoxic Chemotherapy

Breast Cancer | Neutropenia

United States
Cellect Biotechnology

Unknown

Non-interventional, Long-term Follow-up of Subjects Who Completed ApoGraft-01 Study

Acute Lymphoblastic Leukemia (ALL) | Hodgkin Lymphoma, Adult | Acute Myelogenous Leukemia (AML) | Non Hodgkin Lymphoma (NHL)

Israel
Cellxpert Biotechnology Corp.
Medigen Biotechnology Corporation

Completed

Docetaxel With or Without PI-88 in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer

Lung Cancer

Australia
Cellxpert Biotechnology Corp.
Medigen Biotechnology Corporation

Completed

PI-88 in Treating Patients With an Advanced Malignancy (Cancer) or Stage IV Melanoma

Unspecified Adult Solid Tumor, Protocol Specific | Melanoma (Skin)

Australia, United States
Cellxpert Biotechnology Corp.
Medigen Biotechnology Corporation

Completed

Trial of PI-88 With Dacarbazine in Patients With Metastatic Melanoma

Melanoma

Australia, United States
Cellxpert Biotechnology Corp.
Medigen Biotechnology Corporation

Completed

Study of PI-88 in Patients With Advanced Melanoma

Melanoma

United States
Cellxpert Biotechnology Corp.
Medigen Biotechnology Corporation

Terminated

A Phase III PI-88 in the Adjuvant Treatment of Subjects With Hepatitis Virus Related HCC After Surgical Resection (PATRON)

Cancer | Hepatocellular Carcinoma | Liver Cancer

Korea, Republic of, Taiwan, Hong Kong, China
Cellxpert Biotechnology Corp.
Medigen Biotechnology Corporation

Completed

PI-88 in Hepatocellular Carcinoma After Hepatectomy

Carcinoma, Hepatocellular

Taiwan
Sana Biotechnology

Recruiting

Study Evaluating SC291 in Subjects With Severe r/r B-cell Mediated Autoimmune Diseases (GLEAM) (GLEAM)

Systemic Lupus Erythematosus | Microscopic Polyangiitis | Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis | Lupus Erythematosus | SLE (Systemic Lupus) | Granulomatous Polyangiitis

United States
Grit Biotechnology

Recruiting

Clinical Study of GT201 in the Treatment of Advanced Gynecological Tumors (Advanced Cervical Cancer)

Adult | Gynecological Tumors

China
Grit Biotechnology

Recruiting

GT201 Injection For The Treatment Of Advanced Solid Tumors

Solid Tumor, Adult

China
Grit Biotechnology

Recruiting

Autologous Tumor Infiltrating Lymphocyte Injection for the Treatment of Advanced Solid Tumors

Solid Tumor | Adult | GT316

China
Grit Biotechnology

Recruiting

GT101 Injection in the Treatment of Metastatic/Recurrent Advanced Solid Tumors

Adult

China
Grit Biotechnology

Recruiting

Clinical Study of Autologous Tumor-infiltrating Lymphocyte Injection (GT201) for Advanced Solid Tumors

Solid Tumor

China
DynamiCure Biotechnology

Terminated

DCBY02 as a Monotherapy in Patients With Advanced or Metastatic Solid Tumors

Advanced or Metastatic Solid Tumors

United States
EVIVE Biotechnology

Completed

Placebo-controlled Trial of F-627 in Women With Breast Cancer Receiving Myelotoxic Chemotherapy

Breast Cancer | Neutropenia

United States
EVIVE Biotechnology

Completed

Trial to Compare the Efficacy and Safety of F-627 and GRAN® (F-627)

Breast Cancer

China
Sana Biotechnology

Not yet recruiting

Study Evaluating SC262 in Subjects With r/r B-cell Malignancies (VIVID) (VIVID)

Non Hodgkin's Lymphoma | Large B-cell Lymphoma
Grit Biotechnology

Not yet recruiting

Autologous Tumor Infiltrating Lymphocytes (GT101 Injection) in Patients With Recurrent or Metastatic Cervical Cancer

Adult

China
Grit Biotechnology

Not yet recruiting

Clinical Study of GT201 in Combination With PD-1 Inhibitor for Advanced Head and Neck Squamous Cell Carcinoma

HNSCC | Adults

China
Sana Biotechnology

Recruiting

Study Evaluating SC291 in Subjects With r/r B-cell Malignancies (ARDENT)

Chronic Lymphocytic Leukemia | Non Hodgkin Lymphoma

United States, Australia
DynamiCure Biotechnology

Recruiting

DCSZ11 as a Monotherapy and in Combination in Patients With Advanced or Metastatic Solid Tumors

Advanced or Metastatic Solid Tumors

United States, Australia
Grit Biotechnology

Recruiting

GT101 Injection for the Treatment of Metastatic or Recurrent Solid Tumors

Solid Tumors, Adult

China
Grit Biotechnology

Recruiting

Autologous Tumor-infiltrating Lymphocyte Injection (GT201) for the Treatment of Metastatic/Recurrent Advanced Solid Tumors (GT201)

Solid Tumor

China
Maia Biotechnology

Recruiting

THIO Sequenced With Cemiplimab in Advanced NSCLC

Carcinoma, Non-Small-Cell Lung

Poland, Australia, Bulgaria, Hungary
EVIVE Biotechnology

Terminated

Study of F-652 (IL-22:IgG2 Fusion Protein) in Patients With Moderate to Severe COVID-19

Covid19

United States
Cellect Biotechnology

Unknown

Prevention of Acute Graft Versus Host Disease in Patients Undergoing Allogeneic ApoGraft Stem Cell Transplantation

Hematological Malignancies

Israel

Clinical Trials Sponsored by Hrain Biotechnology

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Guinea

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations